{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:28:32Z","timestamp":1753892912200,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Attenuated humoral response to mRNA SARS-CoV-2 vaccines has been reported in some patients with autoimmune disease, e.g., rheumatoid arthritis (RA). However, data of immune responses to inactivated SARS-CoV-2 vaccine in the RA population are still unknown. Herein, the safety and immunogenicity of inactivated SARS-CoV-2 vaccines in RA patients were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Seventy five RA patients and 26 healthy controls (HC) were respectively recruited from Yunnan Provincial Hospital of Traditional Chinese Medicine and the community in Kunming city. Neutralizing Antibody (NAb) Test ELISA kit was used to measure the percentage of inhibition. AKA (anti-keratin antibody) positivity was detected using indirect immunofluorescence. Rheumatoid factor (RF)-IgA was detected by ELISA. RF-IgG, RF-IgM, and anti-cyclic citrullinated peptide (CCP) antibodies were measured by chemiluminescence. ESR (erythrocyte sedimentation rate) was detected by ESR analyzer. C-RP (c-reactive protein) was detected by immunoturbidimetry. NEUT% (percentage of neutrophils) and LYMPH% (percentage of percentage) were calculated by a calculation method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with the HC group, the percentage of inhibition was significantly lower in RA patients receiving two doses of vaccines. Vaccines-induced percentage of inhibition was the lowest in RA patients who had not been vaccinated. In total 80.77% of the HC group had a percentage of inhibition \u226720%, compared with 45.24% of vaccinated RA patients and 6.06% of unvaccinated RA patients. Spearman correlation analysis revealed that antibody responses to SARS-CoV-2 did not differ between RA patients according to their age and disease duration. Furthermore, the results showed that no correlation was found between the percentage of inhibition and indices for RA, including RF-IgA, IgG, IgM; anti-CCP antibody; ESR; C-RP; NEUT% and LYMPH%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study showed inactivated vaccine-induced SARS-COV-2 antibody responses differ in RA patients and healthy subjects, emphasizing the importance of a third or fourth vaccination in RA patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.875558","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T04:59:35Z","timestamp":1650862775000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series"],"prefix":"10.3389","volume":"10","author":[{"given":"Ting","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangfen","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiang","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangyun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaofu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongdong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S0140-6736(20)30567-5","article-title":"How will country-based mitigation measures influence the course of the COVID-19 epidemic?","volume":"395","author":"Anderson","year":"2020","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","article-title":"Spike mutation D614G alters SARS-CoV-2 fitness","volume":"592","author":"Plante","year":"2021","journal-title":"Nature."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12098-022-04077-4","article-title":"The emergence of omicron: challenging times are here again!","volume":"13","author":"Singhal","year":"2022","journal-title":"Indian J Pediatr"},{"key":"B4","first-page":"455","article-title":"Rheumatoid arthritis: common questions about diagnosis and management","volume":"97","author":"Wasserman","year":"2018","journal-title":"Am Family Phys"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/BOR.0000000000000591","article-title":"Patient preferences for rheumatoid arthritis treatment","volume":"31","author":"Hsiao","year":"2019","journal-title":"Curr Opin Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/acr2.11299","article-title":"Impaired antibody response to the BNT162b2 messenger RNA CORONAVIRUS DISEASE 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"3","author":"Ammitzb\u00f8ll","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"102927","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.13495","article-title":"COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases","volume":"202","author":"Baker","year":"2020","journal-title":"Clin Exp Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1136\/annrheumdis-2021-220656","article-title":"High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Ruddy","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cmi.2021.06.036","article-title":"BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel","volume":"27","author":"Brosh-Nissimov","year":"2021","journal-title":"Clin Microbiol Infect."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/S2665-9913(21)00186-7","article-title":"Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis","volume":"3","author":"Rubbert-Roth","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10067-006-0275-5","article-title":"Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA","volume":"26","author":"Agrawal","year":"2007","journal-title":"Clin Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3389\/fimmu.2018.01113","article-title":"Comparison of serological biomarkers in rheumatoid arthritis and their combination to improve diagnostic performance","volume":"9","author":"Martinez-Prat","year":"2018","journal-title":"Front Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1309\/LMZYTSO5RHIHV93T","article-title":"Rheumatoid factor, anti-cyclic citrullinated peptide antibody, c-reactive protein, and erythrocyte sedimentation rate for the clinical diagnosis of rheumatoid arthritis","volume":"46","author":"Shen","year":"2015","journal-title":"Lab Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1684\/abc.2017.1232","article-title":"Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein","volume":"75","author":"Moutachakkir","year":"2017","journal-title":"Ann Biol Clin."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_914_19","article-title":"Pretreatment neutrophil-to-lymphocyte ratio predicts lymph node metastasis in triple-negative breast cancer","author":"Philip","year":"2021","journal-title":"Indian J Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S2666-5247(21)00307-4","article-title":"WHO international standard for SARS-CoV-2 antibodies to determine markers of protection","volume":"3","author":"Zhu","year":"2021","journal-title":"Lancet Microbe"},{"key":"B19","doi-asserted-by":"publisher","first-page":"108383","DOI":"10.1016\/j.intimp.2021.108383","article-title":"Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV","volume":"102","author":"Lv","year":"2022","journal-title":"Int Immunopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3892\/ijmm.2020.4733","article-title":"COVID-19 vaccine safety","volume":"46","author":"Kostoff","year":"2020","journal-title":"Int J Mol Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"724047","DOI":"10.3389\/fimmu.2021.724047","article-title":"SARS-CoV-2 antibody isotypes in systemic lupus erythematosus patients prior to vaccination: associations with disease activity, antinuclear antibodies, and immunomodulatory drugs during the first year of the pandemic","volume":"12","author":"Sj\u00f6wall","year":"2021","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/S2665-9913(21)00392-1","article-title":"Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease","volume":"4","author":"Gao","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221641","article-title":"Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series","author":"Teles","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3201\/eid1107.050219","article-title":"SARS. vaccine development","volume":"11","author":"Jiang","year":"2005","journal-title":"Emerg Infect Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41541-020-0170-0","article-title":"The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines","volume":"5","author":"Shang","year":"2020","journal-title":"NPJ vaccines."},{"key":"B29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-022-04466-x","article-title":"Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants","volume":"603","author":"Wang","year":"2022","journal-title":"Nature."},{"key":"B30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/annrheumdis-2021-221206","article-title":"Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series","volume":"81","author":"Connolly","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e001594","DOI":"10.1136\/rmdopen-2021-001594","article-title":"Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases","volume":"7","author":"Furer","year":"2021","journal-title":"RMD open."},{"key":"B32","doi-asserted-by":"publisher","first-page":"keab879","DOI":"10.1093\/rheumatology\/keab879","article-title":"Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination","volume":"11","author":"Iancovici","year":"2021","journal-title":"Rheumatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1136\/annrheumdis-2020-218068","article-title":"Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients","volume":"80","author":"Favalli","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-858160\/v6","article-title":"Systemic COVID-19 vaccination enhances the humoral immune response after SARS-CoV-2 infection: a population study from a hospital in poland criteria for COVID-19 reimmunization are needed","volume":"10","author":"Kosiorek","year":"2022","journal-title":"Vaccines"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.15585\/mmwr.mm7049a2","article-title":"Comparative effectiveness and antibody responses to moderna and Pfizer-BioNTech COVID-19 vaccines among hospitalized veterans - five veterans affairs medical centers, United States, February 1-September 30, 2021","volume":"70","author":"Bajema","year":"2021","journal-title":"MMWR Morbidity Mortality Weekly Report."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/j.jinf.2021.12.006","article-title":"Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases","volume":"84","author":"Manolache","year":"2022","journal-title":"J Infect."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.022","article-title":"Safety and immunogenicity of SARS-CoV-2 vaccines in patients with chronic liver diseases (CHESS-NMCID 2101): a multicenter study","author":"Ai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity","volume":"41","author":"Fischinger","year":"2019","journal-title":"Semin Immunopathol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"27251","DOI":"10.1038\/srep27251","article-title":"Factors influencing immunologic response to hepatitis B vaccine in adults","volume":"6","author":"Yang","year":"2016","journal-title":"Sci Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/21645515.2015.1093263","article-title":"Primary vaccine failure to routine vaccines: Why and what to do?","volume":"12","author":"Wiedermann","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/22221751.2021.1953403","article-title":"Antibody titres decline 3-month post-vaccination with BNT162b2","volume":"10","author":"Favresse","year":"2021","journal-title":"Emerg Microbes Infect."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.875558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T04:59:41Z","timestamp":1650862781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.875558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":42,"alternative-id":["10.3389\/fpubh.2022.875558"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.875558","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"article-number":"875558"}}